Day One Biopharma Shares Rise on Ojemda Sales Outlook

Dow Jones

Yesterday

By Elias Schisgall

Shares of Day One Biopharmaceuticals rose after the company said it is projecting 53% growth in sales of Ojemda, a treatment for relapsed or refractory pediatric low-grade glioma.

Shares were recently up 21% at $10.81 in Monday morning trading. The stock has fallen 5% in the past year.

Day One said Sunday that Ojemda brought in $52.8 million of sales during the fourth quarter and $155.4 million for the full year, representing 172% year-over-year growth compared with 2024.

It said it anticipates sales in 2026 between $225 million and $250 million, which would represent 53% year-over-year growth at the midpoint.

The company added that it hopes to see Ojemda adopted as standard of care and expand sales of the treatment internationally via an international partner.

Write to Elias Schisgall at elias.schisgall@wsj.com

(END) Dow Jones Newswires

January 12, 2026 09:48 ET (14:48 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2602549368"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2602549368\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2602549368?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-12 22:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602549368","market":"fut","top_or_hot":-1,"title":"Day One Biopharma Shares Rise on Ojemda Sales Outlook","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/DAWN\">Day One Biopharmaceuticals</a> rose after the company said it is projecting 53% growth in sales of Ojemda, a treatment for relapsed or refractory pediatric low-grade glioma. \n</p>\n<p>\n  Shares were recently up 21% at $10.81 in Monday morning trading. The stock has fallen 5% in the past year. \n</p>\n<p>\n  Day One said Sunday that Ojemda brought in $52.8 million of sales during the fourth quarter and $155.4 million for the full year, representing 172% year-over-year growth compared with 2024. \n</p>\n<p>\n  It said it anticipates sales in 2026 between $225 million and $250 million, which would represent 53% year-over-year growth at the midpoint. \n</p>\n<p>\n  The company added that it hopes to see Ojemda adopted as standard of care and expand sales of the treatment internationally via an international partner. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 12, 2026 09:48 ET (14:48 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Day One Biopharma Shares Rise on Ojemda Sales Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDay One Biopharma Shares Rise on Ojemda Sales Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-01-12 22:48</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/DAWN\">Day One Biopharmaceuticals</a> rose after the company said it is projecting 53% growth in sales of Ojemda, a treatment for relapsed or refractory pediatric low-grade glioma. \n</p>\n<p>\n  Shares were recently up 21% at $10.81 in Monday morning trading. The stock has fallen 5% in the past year. \n</p>\n<p>\n  Day One said Sunday that Ojemda brought in $52.8 million of sales during the fourth quarter and $155.4 million for the full year, representing 172% year-over-year growth compared with 2024. \n</p>\n<p>\n  It said it anticipates sales in 2026 between $225 million and $250 million, which would represent 53% year-over-year growth at the midpoint. \n</p>\n<p>\n  The company added that it hopes to see Ojemda adopted as standard of care and expand sales of the treatment internationally via an international partner. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 12, 2026 09:48 ET (14:48 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2602549368","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602549368","pubTimestamp":1768229280,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Day One Biopharmaceuticals rose after the company said it is projecting 53% growth in sales of Ojemda, a treatment for relapsed or refractory pediatric low-grade glioma.Shares were recently up 21% at $10.81 in Monday morning trading. The stock has fallen 5% in the past year.Day One said Sunday that Ojemda brought in $52.8 million of sales during the fourth quarter and $155.4 million for the full year, representing 172% year-over-year growth compared with 2024.It said it anticipates sales in 2026 between $225 million and $250 million, which would represent 53% year-over-year growth at the midpoint.The company added that it hopes to see Ojemda adopted as standard of care and expand sales of the treatment internationally via an international partner.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4539":"次新股","DAWN":"Day One Biopharmaceuticals Inc."},"translate_title":"第一天生物制药股价因Ojemda销售前景而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DAWN":0.9},"content_text":"By Elias Schisgall \n\n\n \n\n\n  Shares of Day One Biopharmaceuticals rose after the company said it is projecting 53% growth in sales of Ojemda, a treatment for relapsed or refractory pediatric low-grade glioma. \n\n\n  Shares were recently up 21% at $10.81 in Monday morning trading. The stock has fallen 5% in the past year. \n\n\n  Day One said Sunday that Ojemda brought in $52.8 million of sales during the fourth quarter and $155.4 million for the full year, representing 172% year-over-year growth compared with 2024. \n\n\n  It said it anticipates sales in 2026 between $225 million and $250 million, which would represent 53% year-over-year growth at the midpoint. \n\n\n  The company added that it hopes to see Ojemda adopted as standard of care and expand sales of the treatment internationally via an international partner. \n\n\n \n\n\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 12, 2026 09:48 ET (14:48 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}